Key result
Enalapril matches captopril in efficacy but provides superior tolerability with fewer distinct side effects.
Why the study?
Enalapril was developed to provide a non-mercapto converting enzyme inhibitor with long duration and improved safety for hypertension and congestive heart failure therapy.
Answers are grounded in this paper and cite their sources.
May support enalapril preference for tolerability in hypertension or heart failure; leaves open prospective confirmation of long-term advantages.
Enalapril is the result of a targeted research programme to develop a non-mercapto converting enzyme inhibitor with a long duration of action and an improved safety profile for use in the therapy of hypertension and congestive heart failure. Over 3500 patients world-wide have received enalapril or enalaprilat. Long-term experience at present includes over 2500 patients. While enalapril and captopril produce similar efficacy, enalapril is better tolerated and appears not to be associated with occurrence of captopril-type side-effects, particularly the skin rash, taste loss, leukopenia and proteinuria. Enalapril and other converting enzyme inhibitors may be associated with renal insufficiency when given to patients with bilateral renovascular hypertension.
No takes yet. Share an insight, caveat, or question.
Davies et al. (1984) conducted a review in Hypertension and congestive heart failure (n=3,500). Enalapril vs. Captopril was evaluated on Efficacy and tolerability. Enalapril demonstrated similar efficacy to captopril but was better tolerated, lacking captopril-type side effects such as skin rash, taste loss, leukopenia, and proteinuria.
Synapse has enriched 10 related papers. Consider them for comparative context: